The role of advanced glycation end products in the development of atherosclerosis

被引：126

作者：

Peppa M. ^{[1
]}

Uribarri J. ^{[1
]}

Vlassara H. ^{[1
]}

机构：

[1] Div. of Experimental Diabetes/Aging, The Mount Sinai School of Medicine, New York, NY 10029, One Gustave Levy Place

来源：

Current Diabetes Reports | 2004年 / 4卷 / 1期

关键词：

Aminoguanidine; Glycoxidation Product; Dietary Glycotoxins; Lipoxidation Reaction; Important Exogenous Source;

D O I：

10.1007/s11892-004-0008-6

中图分类号：

学科分类号：

摘要：

Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Atherosclerosis constitutes the main pattern of cardiovascular disease and leads to thickening of the intima with plaque formation and eventual occlusion of the arterial lumen. A large amount of evidence links advanced glycation end products (AGEs) with the development or progression of atherosclerosis, regardless of the diabetic status. AGEs are a heterogenous group of compounds formed by the nonenzymatic reaction of reducing sugars with proteins, lipids, and nucleic acids. Although AGEs are formed endogenously in the body, diet has recently been recognized as an important exogenous source. An increased understanding of the mechanisms of formation and interaction of AGEs has allowed the development of several potential anti-AGE approaches. Copyright © 2004 by Current Science Inc.

引用

页码：31 / 36

页数：5

共 55 条

[21]

Vlassara H., Cai W., Crandall J., Et al., Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy, Proc. Natl. Acad. Sci. U S A, 99, pp. 15596-15601, (2002)

[22]

Uribarri J., Peppa M., Cai W., Et al., Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients, Am. J. Kid. Dis., 42, pp. 532-538, (2003)

[23]

Uribarri J., Peppa M., Cai W., Et al., Restriction of dietary glycotoxins markedly reduces AGE toxins in renal failure patients, J. Am. Soc. Nephrol., 14, pp. 728-731, (2003)

[24]

Gugliucci A., Bendayan M., Renal fate or circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells, Diabetologia, 39, pp. 140-160, (1996)

[25]

Makita Z., Radoff S., Rayfield E.J., Et al., Advanced glycosylation end products in patients with diabetic nephropathy, N. Engl. J. Med., 325, pp. 836-842, (1991)

[26]

Shinohara M., Thornalley P.J., Giardino I., Et al., Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation end product formation and prevents hyperglycemia-induced increases in macromolecular endocytosis, J. Clin. Invest., 101, pp. 1142-1147, (1998)

[27]

Vlassara H., The AGE-receptor in the pathogenesis of diabetic complications, Diabetes Metab. Res. Rev., 17, pp. 436-443, (2001)

[28]

Sakurai S., Yonekura H., Yamamoto Y., Et al., The AGE-RAGE system and diabetic nephropathy, J. Am. Soc. Nephrol., 14, (2003)

[29]

Zheng F., Cai W., Mitsuhashi T., Vlassara H., Lysozyme enhances renal excretion of advanced glycation end products in vivo and suppresses adverse age-mediated cellular effects in vitro: A potential AGE sequestration therapy for diabetic nephropathy?, Mol. Med., 7, pp. 737-747, (2001)

[30]

Bucala R., Tracey K.J., Cerami A., Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes, J. Clin. Invest., 87, pp. 432-438, (1991)

← 1 2 3 4 5 6 →